PODD - Earnings call 4 2023 | Insulet Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

Thank you. Good afternoon, and thank you for joining us for Insulet's Fourth Quarter and Full Year 2023 Earnings Call. Jim our and and Interim are and Executive Treasurer. today Budden, Lauren Chief me Hollingshead Chief President Officer; With Financial Officer discussing the Investor Both the section of XXXX this of Relations will our website. release guidance on the and XXXX available call be our results, replay press and fourth website presentation. supplemental on our quarter . Also is our earnings encourage to reference of business and metrics you that summary We updates. key document for a

may course be certain that and Before for we our the of made of statements. of Insulet from this during remind SEC inherent explanation call refer cautionary such differ begin, materially statements the Please to forward-looking by could you filings expectations. statements detailed limitations we current a the in

adjusted revenue, in operating believe analysts operating constant interested performance with supplemental These growth EBITDA our and We'll of foreign is effect which our to adjusted performance, and what respect discuss also from investors, financial namely to measures assessing margin, currency helpful non-GAAP growth, align exchange. operating with period we measures of period. excluding revenue and and as measures are measures the performance, to as uses parties management other our they

I'll stated, a the of which percentage dollar commentary financial will be turn call on a the changes be will over Jim. basis. on otherwise regarding that, revenue currency unless year-over-year Additionally, With with all basis rate, to reported and exception growth constant year-over-year

James Hollingshead

which percent automated of eighth which growth joining firmly insulin you in our we With off XXXX thank year Deb. of strong dollar the for almost transformational we revenue us. growth consecutive XX-plus revenue a another million. XX% XXXX, as In market $XXX and established Good we and afternoon, represented growth, realized in Thanks, kept marked results, delivery. our Insulet leader year, QX

significantly also generating flow. cash while positive this and margins free expanding accomplished We

On transforming significant diabetes I revenue growth year forward our to is management. Omnipod which our system, X XXXX with are customer ahead. billion do to record call, today's $X in traction. fueled momentum, new catalysts and discuss growth XXXX, we want entered in a in and market generated Our results first, and global our looking financial of starts many XXXX AID things: X We

update review an efforts developments innovation of pipeline. in provide progress our I'll clinical the and on continuing key Next, then our

on Our into our with growth fourth Omnipod these U.S. of thank of we to of including results, These of orders our minutes. in detail provide expansion. closed expectations, even our the for end including our margin revenue execution team are quarter which global few outperformance and XX%. more a additional Yet we once our Part again dedication. healthy guidance. by driven expectations their exceeded without and I the out remarkable total was this ahead We'll additional XXXX distributors quarter, not factored XX%, placing orders, near had U.S. growth of want

from has of our in Omnipod our customer new We market U.S. as the as recently represents XX% This this almost Type global is year. proud Omnipod time the to diabetes drive of which on most well also XXX,XXX markets. proven continues strong international revolutionary. customers includes DASH Omnipod starts be And X X, in people to milestones incredible active achieved product Omnipod are of XXX,XXX customers impact growth of diabetes. We having platform on which roughly with platform, last on approximately the

meaningful is on our impact are advancing diabetes that the of world. diabetes people unique community, the to improve our making We with around a the thrilled technology mission lives

And to our advantages and AID further are makes pod-based our system. disposable the market. drivers fully diabetes Omnipod daily and our FDA-cleared, adoption. also This leadership simplicity, its of of differentiated reduces its underpin experience product ease are on-body of affordable broad access with dramatically product growth, key X diabetes. and attributes AID the and only the wearable unique fueling and rapid use our living The competitors' establishing offers. is clearly fully in burden key from X Omnipod expertise These position competitive of

significantly building relationships, we creating pharmacy the access in-house decade, in today. channel in a key invested leading building onboarding and pharmacy including expertise, of developing access, which have infrastructure, U.S. an and have strong pathway all a we has almost resulted For deep easy channel

strengthen by pipeline innovation including through building Omnipod's channel We on our continue to our this will access go affordability, that advantages. and

the new to represent QX, trend our customer In in Omnipod vast majority starts expect this X the U.S., continue and to we continue. of

daily pumps use new multiple MDI split. addition, In improved customer at U.S. of even injections as using tubed customer Today, estimated mix of coming legacy people still an with mode percentage The their technology, starts continued care. retention from insulin and most strong. remains XX-XX

to it. gain us, U.S. of for than are care in with largest only diabetes in Omnipod are MDI type customer in writing markets, growing drove both and not continue leadership the people to strengthening position. share our are diabetes starts More This is XX% providers because using majority our a MDI it number was in of pump X XXXX, and drive scripts the people daily U.S. the type AID opportunity Omnipod the Therefore, and and U.S. remains on most type #X X with on prescribed the the of for penetration X type X people X of bringing out health and system and we position vast injections. for

AIB. in choice speak extremely up another We over from X saw which adoption the growing number in confidence now growing and QX, led see It for clear gratifying XX,XXX write we HCPs the demand, growing and scripts of it In QX. to have is Omnipod many a XX,XXX, HCPs to system. is our that to with winning prescribers for increase is

Type any X% continuing leader new pump. already kind with strong We than X adoption using currently Omnipod that Our U.S. in the And that X need we diabetes people we market of customer space. market. that who insulin more intensive in of are therapy are estimate diabetes starts the of no type included know

that diabetes insulin X the as insulin part globally future who confident compelling will care millions to as diabetes of and need a be requiring will are a the of as who millions as We with of to their progress regimen part a naturally prove well today for type simple Omnipod solution their people therapy care.

We positioned diabetes platform benefits in are well to the type of today with future. all of Omnipod X the and the bring people with both

our type patients U.S. In suite between of X the diabetes fourth customer across XX% new our XX% starts and quarter, of products. Omnipod represented

DASH, Omnipod insulin While indication. type have its we type in patients leading this use the operating is once we to expanded with pump Omnipod X look market, indication X an to marketing X for forward

The is underlying apparent. demand

results expect the X XXXX We we FDA of in the an the end pivotal to indication. coming by complete last participant the and to expanded our submit weeks, plan for type to trial

our this starts June. X, ADA our yet to us globally. We our of are deliver to and patients X serve early at trajectory, its success sharing new We in quarter of fuel powerful confident mission. on allow this Omnipod including will European of more customer impact help look be that growth The results another study led another strong catalyst will us to forward markets,

having starts, a Internationally, X Germany. and increase driven of in we in the impact customer realized that's by new U.K. notable sequential Omnipod the

diabetes the in of everywhere by on available. a position plans Omnipod Omnipod majority market these aim customers our early GX care plus accessible remain with us European and launch supports track We our the leader it end to our confidence Omnipod XXXX. European making Our success is X transform X countries as continue X that the with of will of to

Abbott’s with this We X are Libre sensor. new to Plus speak begin a also our thrilled integrated I'll launching in moment. Freestyle journey X opportunity Omnipod to

clinical several In X meaningfully type our we addition are initiatives. study to progress, pivotal advancing other

trial. ATTD X + couple to This included pump non-AID of France. the attend Italy where International are sites Omnipod and weeks the in will randomized a the present RCT excited compared Omnipod GX in U.S. and X data Conference to study We we for in controlled

time in the for a evidence Omnipod with demonstrate population. hypoglycemia, large, are XX,XXX the to X the strength delivering and demonstrating the choice real-world algorithm Technology personalized from low of data clinical diverse diabetes, Omnipod Journal range X are The X's the Therapeutics We recently thrilled published outcomes in care. effectiveness almost Diabetes and people type as very impressive reinforcing real leading in world diabetes and X obvious Omnipod in and have

consistently is mission simplify for over taking people therapy use we is our on people evolution We life want therapy, to Zealand. and study do up to diabetes. place it therapy everything feasibility make This the of our time. for get prescribed set with to New in Central easier to point get

diabetes, study use. either commencing intent completed algorithm and drive in further the then type with or to in type X to X simplicity feasibility at-home participants hotel next-generation have will supervised Our progressing a that of setting We initially use. is first

are the next analyzing with subjects. for and results the round and the modifications of pleased We preliminary are making data

We will results present at feasibility ATTD. early

Lastly, we many and in its tremendous Belgium, September to Omnipod reach in has which France, which enroll in now is and the continue U.K. halfway new physicians study complete. X actively began appreciate and our enrollment pump-naive to trial. our more Feedback RADIANT XXXX, potential integration We X simplicity Libre participants to is been users.

multiple building out help access and as market X expanding Omnipod type the reminder, provide upstream provide as initiatives sensors drive X and digital and the X across pricing with X X our Go superior focus I'll roll our in key now studies X we we and elevate progress Libre we'll on an update a and GX need platform, status moving are Omnipod data areas: innovation market both capabilities. and our to to markets. international therapy As Omnipod on with our the Omnipod further evidence designed first-line our

current heard leading Omnipod market easy product. quickly that system Many us the how it and to our say of made viable has forget you That's given adopted "minimum" Omnipod our X the is have offer. X

and is version integrated moats contains with only operating system, deepen up only continuous Android. current to partner, GX, many our it Omnipod is customers. monitoring only strengthen our that Our open with about Dexcom leadership, glucose X and us X allow was and is until recently, with competitive commercialized X platform change extensions It to more to will first-generation This algorithm. our on

To market start, confident very in release to market allow an with We to over test GX starts will customer Omnipod meaningfully help this we and XXXX U.S. X beyond. our and at build release This will X for our will of a scale launch, which the we weeks. time market full a commenced to anticipate new be last us following in excited of product revenue successful are prepare full initial fuel year. release more GX limited the are have growth acceleration what to

in year with on with also Netherlands CE made limited half this market approval the of planned release and X first U.K. are Plus received our by X the Libre month. Mark earlier track the possible We in we of Omnipod this

both reach We option will X Plus X that Libre us are more patients. for the to many customers Omnipod GX excited and enable with to use

Our both and we want important and choice a CGM of to to catalyst XXXX beyond. Omnipod customers use recent X will our thousands of upcoming growth milestones in and for are providing integrations tens significant who believe integrations be in

are customers for innovation, near-term only GX our use the with milestone prefer because phone. one and we a iPhone major this out carry app to Rounding X system U.S. our This of many iOS U.S. Omnipod so planning our will with mark year. Apple launch innovation of

for Omnipod of further naturally GO, that is receive want simple innovation addressable to people burden and basal-only with more a while reach type their individuals and total avoiding X to will who requiring progress daily us insulin a dose, injections. expand the to way Another market designed allow solution our

the market. positioned we advantages in well patient us Omnipod with X market, in our Our X commercial of GO, clearance we is type achieve our move it DASH will bring for of system the pathway. Insulet for leader type When has X all to in And plans. upstream Omnipod delivery with already help are to pilot people the refine we this diabetes. commercialization the will made AID underway, and Omnipon insulin care

to is X Type require with meets deliver range of of With care. Omnipod people the portfolio these that of their needs X as a an aim our products, full part insulin who

to we massive market we ability this We clear lead excited needs our pursue that and exist will a population. the in market about in and is expect unmet continue the are opportunity. our innovation that space to grow, this global to have the patient It address

to excited build and data also digital capabilities. We are on our

real-time not One Omnipod usage already in opportunity is data AID. on provided constantly needing of the how the data real-time in to every plug real-world connectivity set for from to largest, the physicians us they cloud publish SIM appreciate X data by breakthrough features much has controller. cards and and of patients hear the given We XXX%

to time, on improve the advantages. speed to use we streamline workflows further physician development, and build plan user Over our data the product competitive experience, our

We and coming also continue a set simplify the standard to year caregivers. strong diabetes management Insulet the closing, and for behind In catalysts digital both for and see XXXX products building the us, data-driven we With industry. in to continues beyond. multiple customers

significant We are continued drive success. will and growth we confident

thank to dedication your want for and Insulet deep I our team for your innovation. commitment customers global passion delivering our to and

the world. You are to around to success over drive millions turn to and call life mission Lauren. the the of our continue that, with diabetes simplify the reason our to for our people will for ability I With

Lauren Budden

the and Jim. was was another fourth no quarter Thanks, XXXX exception. year for Insulet, exciting

that expansion growth many X, customer XXXX global, and revenue U.S. also the will the in European long markets. not generated in have by drive only in QX, Omnipod strong momentum We demand starts we new over . our X continued catalysts high the term. margin first with and for fueled strong In but

in to year. a exceeded As revenue a in at tailwind XX% Without these global reported delivered ranges. our foreign was certain last growth hand pharmacy and to in basis results result of revenue, currency from for On benefited distributors, total I'll over still days XXX a base, moment. of in on a Omnipod timing XX%. these We shift growing basis, compared by which of driven growth order increase we an a point customer QX our speak QX, benefits, guidance

growth increased many U.S. X U.S. volume contribution through and revenue our This channel by volume reasons channel for the and to annuity-based going this volume. driven related our Omnipod efforts which to pods be was through from pharmacy. volume resulted XX%, pharmacy the our the all continues and U.S. growing an be spoke U.S. to, in for access pharmacy drive in benefit almost the premium have continues Pharmacy model a increasing Omnipod channel. Jim to includes of

with volume The line remain received recurring orders first from kits our benefit refill and and who consistent net QX was expectations with new we starter in levels. recognized QX customers in their

QX, dynamics not the from in already We expect majority revenue benefit benefited this trend was previously converted. converting volume customers net to expected, Omnipod guidance. continue. Also to since from as had X same vast our immaterial existing In contemplated U.S. the X previously

quarter placed our implementation the estimated our of an million in of U.S. XXXX $XX largest were $XX in accelerated First, new wholesalers million collectively XXXX. of that to pharmacy at ERP orders of from the a system advance first start

benefit $XX of second days as pharmacy their normal million to estimated channel on inventory in increase was to approximately levels. returned $XX an million hand The distributors

not $XX this inventory contributing points called to anticipated, As U.S. half approximately to million below in revenue our had we out is in a million reminder, growth. first XX we QX a in hand of reduction levels. $XX the days normal What XXXX, revenue that down on in to boils approximately

fourth proud market August Omnipod tougher release quarter the to the of in X U.S. performance, especially our full We comparison given XXXX. of are due

QX Additionally, moving down sensor were new customer GX. QX the slightly to market as expected from Dexcom's is starts in GX as from

we business strong, expectations. Overall, commercial are fueled excited launched U.S. starts success growth related by which above demand. to We throughout our International ramp expect as Omnipod very we continued XX.X%, efforts. was release increased XXXX revenue Jim U.S. new X's and as have X market with robust Omnipod accelerate revenue and are our to GX. Omnipod of shared, customer And limited our our

approximately basis, reported versus a and On QX, estimated was X smaller DASH the launches was which prior and our of was starts. XXX and a benefit In year, point foreign from basis both to our the stable. global of in points customer over tailwind trends utilization currency a our remained increases Germany, a continued new U.K. adoption Omnipod favorable XXX guide. drove driven degree, which in by Growth primarily notable Omnipod strong attrition

our points. over almost up a XX.X%, million, Drug was due Delivery which timing. margin basis million was X,XXX increase, to representing Gross revenue guidance was $X.X $X range above

Excluding production points driven XXXX. the the in our adjusted The device support premium channel. expectations become our expectations improved larger increase contributors impact due XX.X% product to pharmacy trajectory, manufacturing This in continues to to costs to the adjusted basis increased margin as gross QX and growth mix. XXXX as efficiencies business favorable in line ramp XXX were corrections, by our in offsetting favorable growth Partially manufacturing globally. for manufacturing up expected launches expenses was costs higher our near-term including medical gearing mix margin gross production. product exceeded a of portion our and volume we a from of and in included favorable primarily with invested the Operating total increased strong that U.S.

Adjusted XXX operating Both was above benefit extent, both were margin favorable a our expectations, adjusted due due to basis million to which point our estimated XX.X% an revenue was mentioned, EBITDA I had to To million primarily XX.X% on $XX impact $XX outperformed and lesser margin. the higher-than-expected adjusted of margin. gross operating revenue.

million lower expense and on $X and almost basis million to credit Loan year the Turning repriced we facility. with interest our We successfully an $XXX cash the ended January, end full rate, At by in under million. B will liquidity. of cash available the which annualized at our a reduce $XXX Term over interest

approximately year also $XX cash generating during turning in of flow million We achieved XXXX. the the free positive, milestone

cash flow. invest flexibility long-term our time financial organization positive drive and our our the free same strengthen position, to continue to at while We expanding growth the us sustainable throughout giving generating to margins

to turning our Now XXXX outlook.

ramp. the realized in most XXXX, year of growth from to X dollar We even significant expect benefits with our Omnipod notably large continue volume another

company end range. We high billion the our expect approach revenue at of $X of total to guidance

For company expect year, the growth revenue total total XX% full XX%. to XX% revenue and growth of Omnipod we XX% of to

total XXXX. reminder, quarter company fourth accelerated to million the to approximately As expectations due X to exclude points $XX of that growth a estimated were $XX our million in the orders

of model XX% our For U.S. channel driven DASH to benefits pharmacy XX% as Omnipod adoption Omnipod, growth revenue and X Omnipod access. recurring we revenue annuity expect well of the from strong as and by

As XXXX, X have retail a and in in stocking a the tougher scripts significant comparison benefits we resulting channel net reminder, volume from XXXX.

points estimated our X expectation periods, both of our is exclude the XXXX XXXX. end When provided color expectations the at of growth. of third our mid-XX% our into normalized range this addition, call approximately growth that into the factoring to due shifted with we In for in orders line quarter high on

starts Also, half is of second and customer app to iOS Omnipod half from XXXX estimated trends, our and release market a half second as with we seasonality a the the to the be acceleration GX. Omnipod we X from expected in due new full immaterial. reminder, XXXX be the expect an following had anticipate XXXX We to with of revenue Omnipod normal of X in lower than first slightly levels of in GO

currently growth new XXXX expect the the cadence be to half offset revenue of our customer the the benefit. partially also of timing stocking We of weighted QX starts, XXXX second more to by due towards

with we in foreign are X% reported basis, revenue For provided previously of of to international high color currency we Omnipod, assuming single impact. we no the On XX%, a which digits. XXXX line expect growth is

Omnipod driven launches to X the and Omnipod Germany. be our from in DASH ongoing U.K. by We expect and recent growth adoption

Omnipod expect where growth. yet we headwinds to partially have do We in offset this continued the not countries X

half time. to with in and enter to in are around GX Libre same Omnipod We Omnipod integrated XXXX, Plus with FreeStyle first X first launch X markets excited the Abbott's another of market the European with our X

to reminder, meaningfully we nature launches growth contribute XXXX. annuity given more a our As expect of model, to our rate in the these

XXXX. a the X low to to second high We additional be due the the a of lesser to continue primarily of high in to launches expect the year year digits, double and, single the our U.K. the to contribution in digits Omnipod range meaningful first range in half and Germany half to to a digits more of launches extent, and single from accelerate

Drug line decline XX% XXXX color we for Delivery, the Lastly, XX% to expect previously a in with we provided.

XXXX to gross margin. Turning

costs XX% mix launches. offsetting and from a benefit expect and associated tailwinds XX% new of product product We favorable manufacturing these higher are anticipated range efficiencies. with Partially to our

of gross market and We due driving accelerating year half the the the In gross operating continued we both first the and while to than expect margins margin higher year be revenue in to plan second throughout to growth. XXXX, manufacturing half efficiencies. expand

expect to lines. functions and to increase we efforts and support invest operating other clinical force and as our product sales our We growth R&D our expand and commercial in including near-term initiatives, expenses

for some large has reps sales expansion pediatrics, a which population focused specifically hiring a always Our on force includes Omnipod captured share.

to many expand have increased margins value, with just Even that. shareholder remain opportunities and we to and investments, we significantly doing committed increase

points adjusted operating from expect margin. operating XXXX XXXX XXXX XXX in unfavorable margins points timing, the We XX%, to $XX higher approximately shift from we year-over-year up approximately order XXX be be impact in operating basis basis in the XXXX. to margin $XX XXX million expect approximately to point over basis million factoring in When

over year expect We second improve significantly half first improvements. to margin manufacturing of during year continued in the and the ramping revenue the operating due half the to

in and further term robust expansion the pipeline the XXXX margin over coming catalysts drive innovation We efficiently have even business growth with our from long in focused commercial considerable investments to opportunities near for efforts. continued many scaling and the and

infrastructure. to expenditures of XXXX spend timing the capital our our double improvement our support manufacturing due to as almost efforts other lesser at as expect support investments Malaysia in to well to new continuous manufacturing from degree, and planned in investment XXXX facility a to locations IT We production

XXXX first guidance. our to quarter Turning

We XX% growth XX%. growth of to company total XX% to XX% of and expect total Omnipod

the growth orders approximately of Our company exclude that due XXXX. expectations revenue into shifted total X points to

shifted For points orders XX% over which XX%, into we XXXX. U.S. X growth of excludes expect that Omnipod, the of growth to to due

a approximately growth impact we of On international XXX foreign estimate For basis expect X% Omnipod, basis, favorable of a reported to points. exchange X%. we

QX In delivery to strategic expect and year be million drug delivered we revenue million. significant to performance approximately we of conclusion, $X another quarter $X and financial Finally, execution.

many We tremendous, of scale efficiently the and catalysts business. opportunities we have and continue global to innovation our in for continue fantastic a an to expansion. with position start and are invest increased ahead strong commitment significant result, a market The XXXX will to are as in momentum grow with margin we Insulet at to

positioned to well value for for on drive are our and our We to long-term customers. creation shareholders mission our deliver

open that, With please the for call questions. operator,

Operator

Our with Instructions] comes question first Bank [Operator from the of line of Steed America. Travis

Travis Steed

to wanted I growth. guidance U.S. on ask about the

change you you it to ago. kind X% provide I how If using guidance. some versus just math before. implies months do it's the But in the get there same do stocking dollars, And clarification and know place. the on Maybe get I you year-over-year XX% just changed like script to growth can the guess you XX% you versus was just no really said of X you U.S. mid-XXs rates, kind the guide if like guide on from which to of

Lauren Budden

Travis, thanks for the question.

So yes, November when really in we much changed view. our just gave it guidance, hasn't in

the $XX we Of million -- remarks, to or was a days mentioned levels. to had $XX I on inventory million in $XX hand an revenue. that shift sorry, As increase in in $XX revenue incremental prepared million million

down the earlier levels we that, first the of the inventory brought have seen half so in year. And

million the that saw to was QX. timing QX a was to in that shift of that. million it, we piece the The So from $XX order of rest $XX

rate, ERP. which that And if about for XX advance range you were contributed our the that, growth to for of of our in guidance to benefit we revenue that, really points our U.S. was achieved So high there. end normalize

Operator

Robbie the question from with line of next comes Marcus Your JPMorgan.

Rohin Patel

for Robbie. actually is Rohin on This

year the well. top elaborate some beyond. in and both key more on well patient You patient XXXX bottom U.S. wondering, margin you as health new growth expansion as the to and lines and drivers great could came off new continued of growth a on I was with if the really in growth as

James Hollingshead

lead there's at which with share. core Lauren for customer market. is comment clearly people I in I'm the starts X the preferred first in main take sure is to take to Omnipod new well. for I'll MDI, up that, new lot of that Wherever starts I We driver new the we may think customer then shot a to customer us, in we -- but want a and take Omnipod most Rohin. Thanks, mean competitor product we the lead as continue just coming X, starts.

U.K., it the available expect So international the to of today X European XXXX, aiming things are majority we've that Then us. already We'll number customers a for half. into to bring get a sensor an have as of our of with market growth to as able drive our offering will be lot the exists Omnipod GX X into the the in in XXXX Omnipod X XXXX we product We're said. in underlying to drive along choice end market for of we to there to growth. of is Netherlands that driver Netherlands the first And markets. as said, in by we'll expansion Omnipod in

And then obviously, GX.

market weeks, weeks X.X to for not weeks, continue about So expectation. have a to of market our GX we a think been and quite than to We've now LMR aim for us. customer release the able year, earlier with GX drive X a new we're bring by will full little couple our accelerate in starts LMR the really bit been to during which excited of

So we're very, excited that. very about

of least leading position -- on her you for there's some Omnipod as sure, which top at growth I'm Lauren, existing our want already drive the want Lauren, pipeline guessing, X. on market in to lot will that will up of catalysts up So of I'm innovation a on But pick you coming well. asked to pick

Lauren Budden

Jim. Thanks, Yes.

had XX% on margin. have of that you an especially and operating we tremendous about And it you XX%. lot adjusted if for It revenue in targets for yes, over QX, our a if we we opportunities was exceed shift, basis. additional improvement, So saw revenue was normalize the

balancing we margin mind of with that will lot keep But revenue, in So we be opportunity. can have that exceed a incremental can if investment. we

product to So a want as growth lot XXXX strategic executing and on to coming in our up, we're new we we imperatives mentioned, of sure make have future beyond. and Jim launches drive

through be So with that the we line. balancing bottom to drop the revenue will

Operator

Your next question comes Baird. Jeff from the Johnson of line with

Jeffrey Johnson

that, your context of integration growth specifically encouraging the especially hear move ] EU to Europe. there advantage I GX O by need ] know about good U.S. in end you and in [ just but [ the O of to not that the as starting that the of in get the you're to are didn't XXXX. then XXXX. X the anything GX I providing can provide majority market to on there, accelerating Dexcom thing. out that that you to has on markets Jim, take hear FMR In XXXX, the U.S. any That's seen. with X you GX in of move GX talking to in color is

guess, I could sounds offset lack So it be integration a 'XX the expanding of headwind GX EU. that in like OX in by

factors, you will? about how do those disparate just we if So X think

James Hollingshead

nice you. and Thanks, Yes. to from hear Jeff,

to call in We about experience. and what very great you're So LMR feel integration driving been the we customers a in a it, make because know we're integration and product with the comfortable you can is way But to here really, see in important. sequencing, right, you you with sure LMR driving it the see in prioritizing it the think customers choice has one -- through the that put with right? that having it learn [indiscernible]. sensors sure as we're way, here. really is to already market make doing about the out as that sensor the we U.S. GX wild, see of are We're going this with And into happy so can we're for a And lot

And that learn the from way and we'll U.S. accelerate LMR a will us allow that in GX then internationally. to in

is Very be the with Libre for GX our way. X right in having in LMR outside that we're the Plus that is in wear guided to RADIANT integration Europe and market. Libre haven't integration great our We as important to LMR working anything Europe a for but which trial timing well. the the customers hard suggest similarly, able the to US that's get experience experience on of The that to trial, on we're now looking accelerate

see we're too. in that from LMR so We'll LMR can you Europe. And accelerating that learn

given guidance the we see geographies, kind and but makes of use if resource sense. on what the that doing kind optimize learning is we're X haven't any for So of can timing we're maximize across -- our to Libre processing the you our LMRs and U.S., parallel

to of to for priority we're and and integrations running really to that get it's can we revolutionary do on get Omnipod Lots offer. be a because to top is on also X. give be Omnipod X -- making on priorities be X what that high customers this. Very our want to sensor -- prioritizing up that's us Omnipod It's proven people to proven want really want drive X. And sure choice Omnipod has to on

into that to the as hard learning as we we way provide quickly optimize working as the So access and to we market. and customers we're we option doing the of it, as working we're can maximize can get to quickly so to various our time geographies make sensors kind can to in integrated hard sure

Operator

with of comes James. Jayson Bedford Our the from question line next Raymond

Jayson Bedford

Just capture on and geographies you'll not And fully gating V launching with the that in kind here new -- factor little quicker is price your what be is year-end. able then into a than international, by to ]? European [ into OP launching expectation of

James Hollingshead

in this talked about question. Yes, we've Jason, past. great -- It been the has consistently

what we're want the which We're mentioned generating the is evidence in RADIANT Omnipod GX X for is to we our we're generate Omnipod need, RCT, we're and need offering establish X our with the trial. first-line comments doing I value across X offering. which doing with as So a extra to we with Omnipod negotiate markets. the international with then levels and go reimbursement the that we creating are commensurate with do evidence our Reimbursement

from to it market. did what launched drive premium. because we channel, pharmacy U.S. the pricing we streamline we in And into the bit different price so Omnipod a our with goal that a full in would time in is X knew coverage the the U.S., DASH when we parity launched It's little because to

different do need It's make coverage. the full is market, reimbursement what In negotiating we body. and to markets, got kind European of we're in we sure So tenders, to every there's on, to negotiate that's those that evidence by conversation. there's need market, ministries we health required market to so able to but have but generate we of have be and the to

So far, we've been very that. with successful

working levels in reimbursement the and Germany U.K., landed in working on. So we're the very with with comfortable U.K., where so in we've

achieve going was factors. then bit every the second really work little drive me it. launch to Gating market. factors, a a X for part by hard to to everywhere And your all and of remind we're it's it gating that question, premium Omnipod the continue different we so And

said cloud it's We're in sort sometimes we've it's a to lot just Sometimes I that our as front. clarify, lined I making preparing of to terrific that want We've everything then do progress. actually, the technical Jeff markets. on just And of and be launch sure up progress of we'd made that. making said, that reimbursement commercial latter think for it's we And just said connectivity. -- is majority

We is that. will European may end majority we end be said technical said the XXXX, XXXX, customers What we've available. of the that What of have on call. the problem said of we X the have by our there haven't a Omnipod by

Operator

next Larry of comes Fargo. line question Our the Biegelsen with from Wells

Larry Biegelsen

on I guide. wanted to follow-up Travis' on question the

from change the So call from and my the question Lauren, is, crux, JPMorgan. QX I anything guess of did

mid-XXs. high implies high the the you said you this end adjustments, you when make So these -- of end said guidance

And historically I curious, XXXX. today. philosophy why new that from JPMorgan year-over-year Insulet there in high that And you end? I'm changed the an anything mean would think starts in at -- I there conservatively. So in grow guided just incremental guidance your is said general, Lauren, your didn't pretty has change? hear comments I was is

James Hollingshead

having we're Larry, call. problem the a technical on

I'm take shot answering best at to your my question. going so And

our nothing so really from guidance, And on guidance. has changed

only guiding we new a in -- to new gave -- to is order the we unusual with guide [ the ramping the the $XX had it's on color margin customer mean, I still roughly pretty and revenue from where forward. compared to consistent is we've color pattern big which color operating the real We're starts November And starts, the on XXXX, think I change customer million giving The XX% given on pulled revenue call. guidance move million is guiding a $XX that that to change gave on we're XXXX. ] we we're the of the actually that for in the call. XX% November increase actually an

change sense. in the guide, a the if XX%, for real from do XXX But number had of which over That what actually prepared XX% because explained November, but to And through the strong delivering we it XXXX XXXX, we we there basis that. you guide what opportunities us forward. XXX like Lauren as points for up what at basis the we achieved high income remember comments, in it than exceeded achieved digits, XXXX, was we only operating really in XXXX delivered XXX are or single have pull we that OI points and to you our is makes and represents of to revenue would now roughly guiding above we're that. end above points And more X.X% ] call color basis ended gave without guided if the which plus, [ well

Operator

Blair. next Our Kaczor come from will Margaret question William with the line of

Margaret Kaczor

number quarter of U.S. details routinely the around HCP prescribers. of prescribers prescribing? to can provide compare Maybe quarter these in continues that? folks prescriptions? quarter. pump seeing on in growth Obviously, a maybe Wanted Are up follow that on you if on Are this any to Curious to grow you that's number does how number the

can the the the open X that or how gets type population, patient And long-winded outside type and of up but X really sorry, Endo's it at part effort. insulin being office scale question, it's intensive a really seen this you is of concept that of

James Hollingshead

great I'll Lauren on welcome and It's start in wants if Margaret. a Thanks, to I'd question. the And back, that. again, chime

we we the -- actually that endocrinologists back of that go assistance, the extenders, either market include X,XXX to practitioners is to past, around quarter, or number the we've a -- we've this which endo prescriptions will in to in know Just prepared prescribers in physician comments are so-called getting somewhere beyond nurse X,XXX that. endos this the pointed We have we're clearly but context, their U.S. out themselves XX and but put didn't physician

believe we have into perfect PCP practices, out data. practices it don't We're in continues endo and in see clearly it that which practitioners. more getting direct-to-physician various we and our insight can prescription our and also word writing smaller direct-to-patient and health the outside that's available reaching data. grow, can of dynamic in of and include we're activities practices, We through to But activities, online. own see activities both care through we're we that more mouth, promotional doing promotion And of

commercial could that." they in there's a just and for we're see a you across We practices for And learned has care. very the very for easy. the investment Omnipod, the demand drive so patients I'll lot never us, primary say a dynamic, that lot of with And this be we're they "Wait, Omnipod we're when target what, say, along a that's we've pump, platform think then same the to thing things able would a people that know what bit -- we've thing learning the couple lines. going other primary year for diabetes. us confident proven And population about it's GO they powerful about been tube think Omnipod, is to because little seeing, do patient that. happens more so to Omnipod could My primary care with a do we're be and learned that of prescribe of then they [indiscernible] what care they when terrific learning pilot The very, [indiscernible] sort a living we're channel for the

than X the in care And patients we I think seeing anticipated channel. type more we're primary

it a So where to learnings out most. Omnipod to and continue of drive able for patients as we of for therapy Go your our really going that point, the world therapy to need -- to into kind Omnipod new Omnipod driving driving demand pod avenues new we're pilot, be optimistic find we're very

that. about optimistic very we're so And

we with positive us, continue really for that we world in as see learning as what commercial so go. our we're pilot to we're trend signal about but out excited a And the

Operator

will TD with line Jennings next come of Your question from Josh the Cowen.

Joshua Jennings

through X and Insulet pricing 'XX. receiving to dynamics was XXXX? channel factor stable Was I levels in was we for reimbursement for DASH in and DASH And pharmacy for the hoping and X U.S. that reimbursement Omnipod and understand in the just Omnipod Omnipod should pricing X Omnipod in how better DASH.

Lauren Budden

Yes.

a into did So volume channel. largely the those really, complete previously, a price big by But point. get about We business this are as pharmacy at from point. this it's XXXX more mentioned conversions we've conversions throughout the lift

a line was do So that We adjustment. in have like normally going minimal. of seeing X% not did price pretty the with we of forward. kind in cost just early increase It's we're September, living which under

the wholesaler we just fees. in in some don't of though, that of terms of and it the benefit there, DDM So because mind the see full goes to keep rebates to

but much incremental should are shouldn't an great change. price pretty lift going continued on not be it say So I the that we that volume, price point, this getting the focus at for leveled you XXXX, off. The news is would has forward, that

Operator

comes of question Wuensch Citi. Joanne the next Your with from line

Unknown Analyst

and This on term, margins beyond potentially is XXXX kind go and can Joanne. get how for XXXX over as ], gross [ investment and talk year XXXX is margins could operating of longer maybe well. Anthony you there? But you where the

Lauren Budden

Yes, that Jim to margin for Yes, longer happy have on. We expansion, gross through. to QX, and more free able top product we to accelerate the in with like in both definitely have line and allow then be near off up as we term this year have opportunities the the setting start add drop margin will term. feel and lots we I'm on feel great did and we're that to in we the of room launches us and

doing we but planning plan later long-range a this in XXXX, on beyond are guidance out put haven't We year.

Operator

Piper come will O'Brien question next Your of with the line from Matthew Sandler.

Matthew O'Brien

to is going I promise. It be one question,

the part down stock question mid- earlier, single kind digits more upper looking first just the kind at to of I'm in is but The Larry's aftermarket. of to clarification

where XX%. worried should of just a the been that that XX%. I high commentary. And it we to think issue guidance there's I'm again, end this it's pharmacy sure related or really be at nothing street modeling making you versus about? the have it competitively on XX% Was XX%, range should gets

start with went Jim, is, back out guys when to question to X, year? course you tougher to competitive the real conversions? I we're the to XX/XX GX, with competitive came and from XX-XX. think Is then easier MDI it way will now throughout little it you then do XX-XX, getting conversions you And of tougher get a and take this think all to little the that XX-XX, went those bit a O And better, bit to

James Hollingshead

Why on up on Go don't guide pick the the -- we'll Lauren then have Lauren. start and I'll competition. ahead,

Lauren Budden

Sure.

realized revenue we're So guarding very for to volume growth. XXXX, even we with benefit strong 'XX, that in the significant

in billion growth our terms dollars. represents in and $XXX We guide of expect of revenue million $X achieve almost to revenue

provided, your terms of advance revenue So would question were it to -- million XX QX was but ERP the in million were we just that from shift XX have in call placed really of implementation. of orders our changed that what of been

X company total estimated impact the the on and on U.S. that Omnipod. of points is X So points

the revenue the our and growth and overall, starts have 'XX is help we mentioned, particularly year half back guide beyond. for into to going with and that's customer in and as strong catalysts And So accelerate in we've it new strong. XXXX many growth provide those for

Deborah Gordon

normalized was I is say just modeling thought on heard you now nailed a U.S. Jim. going I it. basis. sorry, say to you that, I The XX% that I'm Street

I exactly a the X-point it right if when U.S., for the nailed normalized said that on year impact. that's Lauren And basis. you that right that the got she said So

there. And on QX company we to you So what about mid-XXs -- we normalized growth on XX of provided it spot midpoint, total XX%. about Lauren would XX% the that on at ] for you math, and were some do expecting And gets a XX when be to [ referring to color in we're the call around basis the that's Omnipod for total if to U.S. the

shift, million on ends happens, shift comes up November. to million Lauren year it's to goes of double, to $XX out spot $XX the which that million into other. in XX just to ends that $XX $XX color it's the up didn't being XX because right, and million We expect the that from gave So X or is the

actually set. So she to trying that's normal where was

So answers that your question hopefully, that on piece.

Sorry, Jim

James Hollingshead

-- number, in the offline, 'XX, that normalized and million. we $XX you the a can always right? clarify it's increase $XX this decrease in for right? a denominator, So numerator but So double to whammy get it's the million in

underlying the the guide So respectively. same, remains

continue of and we On starts. And good competitive always the had new competition, switching. to we XX/XX have customer historically, MDI really yes,

caught really, of well. launch of X, the and really After lot Omnipod we've competitive switchers, done we a obviously a

We continue to have.

customer and switches competitive So a because and retain starts very are the number customers competitors. of XX% if you overall, underlying new of from about to than majority do it switchers, very, pre-Omnipod-X well. that it's vast X right? larger So up so with of think we was, Omnipod and we continue competitive And is that we get XX% dynamic there also the

say we in the their has fundamental that a the one would Retention is happening But any calls, we had market. be little the around very, installed hearing now and continues X And shift X We said see the competitors' that, Omnipod our dynamic. of preferred benefit of of don't we the staunching out don't do We what's benefit base. competitive competitors there's strong. see I our very say. have better think the would the product. done bleeding seeing job I -- underlying in edges, we things -- in to of

can the on with little you starts with MDI we're in clearly and -- And bit offer very, market. winning winning still market. the But very going that overall of clearly see so dynamic clearly a preferred customer in new the just

Operator

Your Kratky with Leerink Partners. next from Mike question comes

Michael Kratky

to on on into in in defending you access. with XXXX. additional to pharmacy position the are start capitalized basis market a we then broad planning ahead near-term and advantage both you've on pharmacy competitive the that see So having pumps type How X as channel expand looking a

James Hollingshead

it's X better And the -- all pharmacy is Omnipod tubed there's our day, pumps the offer platform channel offer pumps to the to just the much that AID. are, much, better is we've to get channel suited. durable kinds surprise this, to go I but channel into out tube equipment. successful of talk we about figure things Thank end the here durable of much suited I'll trying and a not so in pump Pharmacy see for -- Great can a the how pharmacy the been with that competitors because weeds continue say question. be than you. at pharmacy in establishing

we've us a It's there's economics or very pump curve the very, different in it's for is the work channel, DME it's market from going And whether of what established very and range a to leadership competitors -- we've basically big -- competitors as expect, learned -- are that. chase offer It's would we our there's pharmacy. is, there's the whole are across learning the actually because cases, pod. value the better the -- in all durable in pump,

the that the the channel, contracts fact it PBM pharmacy our very with very we've coverage fact that all we our the in to that little that pod have but And Couple a consumable, with advantage in wide successful created growth it starts have the as And very, as of channel. we advantage across gives us in partners. which inherent an is we established had get -- value us an abstract, is the we're gives inherent PBMs.

retail into we go pharmacy to their think whether have a very insulin, insulin the who use get We getting they're pharmacy. position there. [indiscernible] People defensible it

and So AID-pump channel be of to be and their continue continues them therapy for positioned as positioned pharmacy very in the the it's go great we prop place will forward. to value a very to Omnipod also uniquely get uniquely Omnipod

Operator

the Pasquale next will Chris with Your line of Nephron. from question come

Christopher Pasquale

full so I it comments think launch? full far boxes doesn't on sounds GO to sound like your do How the need GO about for anytime a that's before really there? ready what It you gating well. are isn't the to 'XX, heard Jim, thinking And the pretty interesting. guidance really makes check I really any assume learned What what's the launch from the benefit you've you in you're commercialization? timing LMR were from soon. expand going which like factor planned But a

James Hollingshead

last limited not pilot, GO, The market to with on -- just right? is fully about a I And we're think The I Yes, that before Omnipod I'd we about GO great be a question. language is said our out patients, approved. different that's this. well, itself before that's in call as commercial ready. in product release so It's really LMR. a hear a we're way think And clear, step step this quarter on an it's

We continue for coverage it. grow to

So that's but step coverage. we're of a ahead and schedule

is way model, both So we excited of one so is factor about about GO commercial the what to an we're it And right? chain. for learning, awful think pilot the care is reasons that we're is commercial pilot. for the for lot out the and of right GO learning gating are to pilot timing, not primary the the Omnipod it's the So establish using that

commercialize sometime in points 'XX be this one or land in where to land is and with we're whether we're the and to another, channel to of in second, call we're -- FMR where 'XX, we going primary going care first we're thing, have in more so to commercialize in GO going on an primary -- care. or to going or And 'XX way get

people the need we for type will the is who diabetes with X offering broadest delivery. insulin have And other thing living

So -- pivotal that our we're with going clearly. already the trial We in market space X. Omnipod very we have DASH know to leader

have and but have As X have our for cases, label. In order we're out our people using off-label, plan in the being and label the pivotal the X that of the to short label with initiating I'm X, promoting a to gives goal insulin we'll is all not -- the intensive Omnipod continue X Omnipod Omnipod used is of insulin. you have we'll I'm off a lot we extension FDA X from insulin type that we And coverage whole said know using actually before, way we GO. file with to trial, coming Omnipod in for for basal 'XX,

full and that have we'll and of way And both in care clear endocrinology primary portfolio very to channel. so have a products, commercialize the in that we'll

with I'm Omnipod So commercial that's I'd GO. very pilot why say about the excited

We portfolio on we get into going are better ton make and that commercially market. get us and that to the much learning full it's as

Operator

the will next line Our question come Steve with from of Lichtman Oppenheimer.

Steven Lichtman

U.S. us U.S., you what start As that latest your outside size on to the give in the would the Libre of like. you opportunity. to latest that. your on be get the can then opening There's thoughts on color been that great platform new and opportunity here opportunity It up the set estimates looks

James Hollingshead

a big We think Yes. it's opportunity. really

using the market, at you've sensors millions sensor look Abbott's millions you people got and of If Dexcom people sensors. of using

integration and across So X now Libre Libre that range. and emerging -- the Libre X family products GX, creating the products family GX by the

main us with working the it Europe to U.S. both of prioritizing partners. to on-body an opens they strong. but us. prioritizing the pays have really of for geographies always them them an positions of we much installed Libre So jump have an then used have, sensor and large plus bases. for it in their in experience that good GX, on-body technology. for get is road said, them with of Omnipod. easier because base, Development them CGM They're The we're both -- and a great both makes people with X terms to of They market very having installed both And then partners. working as have we've experience love different X and our in slightly really substantial X both with parallel. pathway -- of It both really up They're a large slightly

share opens think we the estimated it market ready who experience. think of and share, up can people CGM the will for on-body up Omnipod Libre installed because market base And but partners, to the a so U.S. the at X -- Europe both integrations you go used open for they're we our in a large look be

Operator

line the of will from Thibault Your question with Marie BTIG. next come

Sam Eiber

XX% Just type for from pivotal data ADA and coming get up Marie. label for an already filing label be at on just of expansion, X? And that looking some once coming are considering uplift there? comments. at how can the Maybe on up XX%, I the of then do expanded Sam follow starts of X could much you new patient type

James Hollingshead

Sam. Thanks,

in look with about, and are we size shared therapy. end somewhere million just million something X AID XX% less is between basal-only and the repeat X Then the on with therapy. than the people if market are type of living penetrated living market, markets the type million U.S., people there you type X who there, X at X If numbers X.X I'll In probably, that before. And diabetes. about there that are with

And the intensive so somewhere type with insulin need people plus X.X therapy, million living basal bolus. U.S. in who X around

population, intensive X% know about at the clear DASH aimed of Omnipod the million in really therapy plays it's AID that is people we're We that we current segment in that, has know market And U.S. label already leader market a than less therapy. and because there, that in therefore, with a in X space. than larger X the the Omnipod penetrated leader market market the market now Omnipod And are we X.X is label. end insulin with its

very we're why type so the is to X managing takes in use. successful that of a burden lot it's of larger population, very off we're a intensive been X value very than market optimistic. end the It And in the So easy That's your today. which Omnipod diabetes. going population. X type optimistic we're into using one insulin playing the proposition is about

it way, to important by think a and is a opportunity the market grow that, continue we time. So really over will

Operator

We have more X time for question.

from with final of Danielle Antalffy line the Your comes UBS. question

Danielle Antalffy

into quickly? about unpredictable. you something on now happen of to patient. there? the off whole in on sort sense to that's goes much is how get of I stocking But shelf thinking But the and the start to have because wholesaler to fit How question single on a going they're could do and that a guess quarter, a model, qualitatively, we this the level it visibility have trying very that going you stocked stocking to long the Just shelves I it's is that dynamic about every when maybe know talk something gets if this pod

Lauren Budden

No. a on the pretty long. channel. really doesn't I it mean mean that we it's -- I shelf stay efficient

that into something our visibility something control. included In not we hand we ever guidance, that terms that's date of the can't the and though that's on in

quarter, taking earlier inventory And in back this pull year. we had then ERP dynamic. after whammy so down up And unfortunately, forward of taken they them the same the double them time, the level we had had the at the

again, we So out something in when it to call when I we you not like our guide that we see expect and we we the do what have something is, we'd control. it. of to It's But this, ability have don't magnitude. that happens, don't tell something

Operator

X And Barclays. with That question. we the of Miksic Matt question for do will have more come line time from

Matthew Miksic

Great.

GX going you're you question year, do then that the having certain, clinic? XX had new is ask the seem the What [indiscernible] be, that maybe new And more. seems to GX a but I months on so, and capturing there's patient maybe be mean maybe patients very very from of your bit a share like So -- not would is that to of tubeless already at X-parter and high catching I end, on the you're of back point, course, the certainly in patients. what's it's it's just integration. of a or share looking some mentioned given just And or -- news get could, it good additional that you now, acceleration looking one at and you're out high advantage the competitors growth, another not question, if you with market I other news in challenging pump the for of

if think I about just grow prepare for how maybe in investors And how do think you we segment? How leadership can look about that? think -- your that do that continue your -- so to And should about that? you do you potentially. how And

James Hollingshead

order. do in those Thanks, Matt. I'll reverse

there tubeless convenience, to frame with right set that about on even what see, experience, competitive scalability, on just confident The very in as our the can in is form insertion, one that's whole in we we publicly have we what can. see watch of of market anything we X, ease time the package, first the pipelines terms position. the competitor wear out of closely that in that obviously our as close the now needle use, is the the in Omnipod don't And are feature and we automated We go factor. we coming on could terms

never We're complacent.

what know X in a because has have we and respect successful, chase lot to so our Omnipod of We -- it. wants competitors, general, that Omnipod for but been everybody

how competition are position, that's But and and in makes what in matches we continue anything sense, even competitive very drive see to innovation. works. our we're have, coming don't just confident we that So to pipeline going we and that anybody's

So extend we're lead. our going to

it product, with and you're with starts. script you're so part obviously very see look viable on really seeing doing data, at is But offer. the On market GX your we it's first doing GX good specifically go really the remarks, the I our Yes. can seeing what our We're really we've well it's and minimum the is underlying question. it's done -- the in new as analytically -- question, in with said customer as it. prepared GX, And well of a really and well existing you very, what

guys have use to ], probably heard So a you've metaphor lot people GX. of about going [ you this on corny is heard the but And before, fishing. me

the pond, and but it, lot the we're it's GX more the fishing all think in in pond more stock of has a out you GX If time. it got in

growth and in We is part mix fish bonds going wind going the larger drive for and want lot at of market. know the proportionally, be all there go want I'm And of GX to patients -- X a and Omnipod able with that so GX a GX us we our metaphors. just be the together, larger We had. like under of X coming and out to is and We now to to both back want terrific GX. to Omnipod offer

Operator

would to the I to conference Jim like This turn Q&A back concludes our section. Hollingshead.

James Hollingshead

everybody, you, joining today. us for Thank

to cash improving and and with We through for year focused Insulet committed experience. driving We growth. customer extending on deep passion thank to are flow dedication really excited wish emphasis while thank want our for We're focus our and their for I evening. once you also margin remain outstanding expertise Insulet. value all innovation strong customers. our on and excellence further their position the our generation, emphasis again all everybody. our maintaining leading on I'll delivered team all to have Good that, our another a Thank for investing to everybody. expansion operational shareholders you, innovation, with on outstanding night, global and great you and And

Operator

this gentlemen, Ladies wonderful participation, concludes and a conference. your have Thank you for day. today's and

disconnect. all may You

Insulet (PODD) 22 Feb 242023 Q4 Earnings call transcript